Alcon, Inc. has purchased Neurotech Pharmaceuticals, Inc., developer of the first and only FDA-approved treatment for Macular Telangiectasia Type 2 (MacTel).
Big news … let’s start with what we know about this deal.
Alcon shared two details surrounding the transaction:
- The company paid $550 million to acquire Neurotech, with the understanding that it may also be required to make “additional contingent payments.”
- These may occur upon certain commercial milestones being met.
- The deal is expected to modestly boost sales growth and slightly reduce adjusted earnings per share in 2027 before adding to earnings in later years.
No other information was provided.
But let’s not forget: With this acquisition comes ownership of that aforementioned FDA-approved MacTel treatment: ENCELTO (revakinagene taroretcel-lwey).
A major acquisition indeed … but first, a look at Neurotech.
Headquartered in Cumberland, Rhode Island, the private biotech company has dedicated its operations to developing sustained drug deliveries for chronic retinal diseases.
- Its primary focus: MacTel.
As for its flagship product: ENCELTO was granted FDA approval in June 2025.
The basis behind this treatment: Neurotech’s core technology known as the Encapsulated Cell Therapy (ECT) platform.
Give us a quick rundown on that.
This cell-based drug delivery therapy platform is designed to continuously produce and deliver targeted therapies (singularly and in combination) to the back of the eye for the long term.
- Its foundation: Is the customizable NTC-200 cell line, which can be genetically engineered to produce “clinically relevant levels of therapeutic protein.”
- See here for how this platform targets disease (including an overview on its delivery process).
- Also check out how it differs from standard injections (hint: this involves control over the drug dosage that’s delivered to the eye).
Got it. Now tell us more about ENCELTO.
This ocular implant relies on the ECT platform to deliver therapeutic doses of ciliary neurotrophic factor (CNTF) into the retina to slow disease progression.
- In the context of MacTel: CNTF is known to have a neuroprotective effect on retinal degeneration by protecting against photoreceptor loss in MacTel.
Got it. What else?
Per ENCELTO’s prescribing information (PI), it’s indicated for the treatment of adults with MacTel via surgical intravitreal (IVT) administration.
- See here for the recommended dosage and administration guidelines.
Also worth noting: The implant was assigned a permanent J-code in September 2025—shortly after the first procedure was performed in the United States.
Alrighty, so how does this purchase benefit Alcon?
We’ll start with the obvious: With ENCELTO under its wing, the global company is expanding its retinal portfolio in a big (and groundbreaking) way.
Why? Let’s not forget the implant’s approval marked the first treatment for MacTel.
Even further: CEO David Endicott referred to Neurotech’s ECT platform as a “highly complementary addition” to Alcon’s existing capabilities as it continues to work toward its “vision for the future of retinal disease treatment.”
And for Neurotech?
Alcon’s purchase means greater patient access to ENCELTO—across the globe.
As Neuortech CEO Richard Small noted, the company’s “global scale, commercial capabilities, and scientific expertise” will support the implant’s expansion into more markets and patients.
Lastly: This isn’t the first business deal Alcon has been involved in recently, right?
It’s not. Although—it is the first successful one this year (to note: it acquired LumiThera in September 2025).
If you recall: The company’s previous attempts to merge with Lensar and STAAR Surgical fell through earlier this year: see here and here, respectively, for those details.